Navigation Links
Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease
Date:5/20/2008

n observed in patients receiving Cimzia(R). Some of these infections have been fatal. Anti-tuberculosis treatment of patients with latent tuberculosis infection reduces the risk of reactivation in patients receiving treatment with TNF blockers such as Cimzia(R). However, active tuberculosis has developed in patients receiving Cimzia(R) whose tuberculin test was negative. Evaluate patients for tuberculosis risk factors and test for latent tuberculosis infection prior to initiating Cimzia(R) and during therapy. Initiate treatment of latent tuberculosis infection prior to therapy with Cimzia(R). Monitor patients receiving Cimzia(R) for signs and symptoms of active tuberculosis, including patients who tested negative for latent tuberculosis infection. Consider anti-tuberculosis therapy prior to initiation of Cimzia(R) in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed.

Serious infections, sepsis, and cases of opportunistic infections, including fatalities, have been reported in patients receiving TNF blockers, including Cimzia(R). Infections have been reported in patients receiving Cimzia(R) alone or in conjunction with immunosuppressive agents. Do not initiate treatment with Cimzia(R) in patients with active infections, including chronic or localized infections. Patients who develop a new infection while undergoing treatment with Cimzia(R) should be monitored closely. Discontinue administration of Cimzia(R) if a patient develops a serious infection. Exercise caution when considering the use of Cimzia(R) in patients with a history of recurrent infection, concomitant immunosuppressive therapy, or underlying conditions that may predispose them to infections, or patients who have resided in regions where tuberculosis and histoplasmosis are endemic.

Use of TNF blockers, including Cimzia(R), may increase the risk of reactivation of hepatitis B virus (HBV) in patients who are chronic carri
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
2. Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients
3. Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone
4. New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain
5. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
6. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
7. Gene Therapy Provides Vision to People who Were Nearly Blind
8. Arpida Provides Further Comments on the Pivotal Phase III Trials
9. Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology
10. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
11. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Ranibizumab Market, 2012-2019" report ... was approved by CFDA to treat wet age- related ... product of Novartis, is available in the Chinese market. ... drug for the treatment of wet AMD in ...
(Date:8/28/2015)... , Aug. 28, 2015 Perrigo Company ... on the Mylan N.V. ("Mylan") (NASDAQ: MYL ) ... Perrigo. "Our views of Mylan,s offer to ... be, based on our Board,s careful reflection of the ... on the limited choices that Mylan has allowed its ...
(Date:8/28/2015)... and PITTSBURGH , Aug. 28, ... today announced that its shareholders have approved Mylan,s ... PRGO ; TASE) and the related issuance of ... extraordinary general meeting of shareholders held today. The ... at the extraordinary general meeting. In addition, the ...
Breaking Medicine Technology:Investigation Report on China's Ranibizumab Market, 2012-2019 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9
... Inc. (DCI), announced that the company has received ... its New Drug Application (NDA) for PERTZYE™, indicated ... due to cystic fibrosis (CF) or other conditions.  ... enzyme product containing bicarbonate-buffered enteric-coated microspheres and is ...
... Inc. today announced that company personnel will deliver a ... Week (DDW) annual meeting at 9 a.m. PDT on ... Center in San Diego, California. DDW attracts thousands of ... share the latest research in gastrointestinal health topics, for ...
Cached Medicine Technology:Digestive Care, Inc. Announces FDA Approval of PERTZYE™ (pancrelipase) Delayed-Release Capsules 2Receptos to Deliver Scientific Presentation at Digestive Disease Week 2012 about the Therapeutic Role of RPC1063 in Inflammatory Bowel Disease 2
(Date:8/31/2015)... ... 31, 2015 , ... Intellitec Solutions announced they have reached a record for ... new staff member in 2015. With the potential for more hiring occurring before the ... Dynamics GP, Dynamics SL, Dynamics CRM and Intacct, and has hired new support staff ...
(Date:8/31/2015)... ... August 31, 2015 , ... healthbeautydistributors.com has been in business ... marketing a doctor note service to be made available to all patients and ... each generated excuse, much less than the average daily pay of workers. ...
(Date:8/30/2015)... California (PRWEB) , ... August 31, 2015 , ... Avid ... Morrison and the Doors Shrine Auditorium concert posters. This hand colored artwork is one ... and 23 in Los Angles. Hawley states, "When the doors played the Shrine, ...
(Date:8/30/2015)... ... 2015 , ... ChopChop Kids, the nonprofit publisher of the ... two new officers to serve on the organization’s Board of Directors in accordance ... kids to cook real food with their families and help continue to drive ...
(Date:8/30/2015)... ... ... Scientists in France say asbestos exposure may put workers at higher risk ... just posted an article on the new research. Click here to read it ... 2,024 French asbestos plant workers from 1978 to 2009. In addition to mesothelioma, the ...
Breaking Medicine News(10 mins):Health News:Intellitec Solutions Achieves Record Pace for New Hiring 2Health News:ChopChop Kids Appoints New Chair and Vice-Chair to Board of Directors 2Health News:ChopChop Kids Appoints New Chair and Vice-Chair to Board of Directors 3Health News:Researchers Say Mesothelioma Not the Only Cancer Linked with Asbestos Exposure, According to Surviving Mesothelioma 2
... in as the 5th Chair on "The Doctors", LOS ... be the guest co-host on the number one new syndicated,talk ... (check local,listings, http://www.thedoctorstv.com )., Best known from the ... York Times Bestselling Author for his book, Billion Dollar Smile,sits ...
... fatal parasite; first vaccines delivered following major funding award. ... that could eradicate a fatal form of brain disease ... soon be commercially available thanks to multi-million dollar funding. ... million tapeworm infections and 50,000 deaths from brain disease ...
... Abbott (NYSE: ABT ),will present at the 17th ... Thomas C. Freyman, executive vice president, finance,and chief financial ... 5,p.m. CST., A live audio webcast of the ... at http://www.abbottinvestor.com . An,archived edition of the presentation ...
... for stroke ... treatment, ... a team,of stroke experts from the West Virginia University Health Sciences ... The study showed CT perfusion had,100 percent accuracy for detecting the ...
... of America, Inc.,(OTC Bulletin Board: CPCF), a company ... in endovascular procedures, today announced,that it is implementing ... its MedClose(TM) investigational-stage medical device. In,the roll out ... Medical,Product Service GmbH (MPS) of Germany to act ...
... Emergency Room Life Through Eyes of Poet Doctor, ... care,crisis in America to the natural fear of illness ... wonder and poetry in medical practice.,Bertrand P. Fote has ... his,work as an emergency physician, and he captures this ...
Cached Medicine News:Health News:Celebrity Cosmetic Dentist to Guest Co-Host New National Day Time Talk Show 2Health News:Fight begins to eradicate fatal parasite; first vaccines delivered following major funding award 2Health News:Fight begins to eradicate fatal parasite; first vaccines delivered following major funding award 3Health News:West VA University Study Calls for New Method of Stroke Diagnosis 2Health News:West VA University Study Calls for New Method of Stroke Diagnosis 3Health News:West VA University Study Calls for New Method of Stroke Diagnosis 4Health News:CPC Appoints Medical Product Service GmbH as Authorized European Representative for MedClose(TM) System 2Health News:CPC Appoints Medical Product Service GmbH as Authorized European Representative for MedClose(TM) System 3Health News:Physician Portrays Powerful Poetry at Heart of Human Condition 2
Trans-Blot Plus Gel/Cassette Assembly Tray...
Ice block will provide sufficient cooling for most normal blotting applications. Sealed block is held submerged in transfer buffer. Ice block will not spill during refreezing....
... Pens-Using a proprietary and patented technology, ADI ... called Antigen-Antibody pens-TM, that will allow researchers ... in any form or shape or size. ... to see antigen being written on the ...
... Advantages of using the Antigen-Antibody Pens-Using a ... and developed specialized fountain pens, called Antigen-Antibody ... or write/mark the blotting membranes in any ... formulated antigen-bonded colored dyes helps to see ...
Medicine Products: